Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,819 across all filing types
Latest filing 2023-07-28 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2023-07-28 English
Earnings Release 2023
Earnings Release Classification · 1% confidence The document is titled "Genmab Updates 2023 Financial Guidance" and presents preliminary first-half 2023 financial results along with revised full-year 2023 financial guidance (Revenue, Operating Expenses, Operating Profit). This content structure—presenting key financial figures and forward-looking guidance updates—is characteristic of an Earnings Release (ER). Although it mentions the full results will be published later, the core content here is the immediate release of key financial performance indicators and guidance changes, which aligns best with the ER definition (initial announcement of periodical financial results/key highlights). It is not a comprehensive Interim Report (IR) or Annual Report (10-K), nor is it merely an announcement of a report's publication (RPA), as it contains substantial financial data itself. The document length (7722 chars) is sufficient to contain meaningful highlights. H1 2023
2023-07-28 English
Genmab Updates 2023 Financial Guidance
Earnings Release Classification · 1% confidence The document is a 'Company Announcement' from Genmab providing preliminary first-half 2023 financial results and updated 2023 financial guidance. It highlights key financial metrics (revenue, operating expenses, operating profit) and explicitly states that the full financial results will be published on a later date. As it is an initial announcement of financial performance highlights rather than the full interim report itself, it falls under the Earnings Release category. H1 2023
2023-07-28 English
6-K
Foreign Filer Report
2023-07-21 English
Regulatory Filings 2023
Regulatory Filings Classification · 1% confidence The document is titled "Company Announcement" and details the positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the conditional marketing authorization for the drug epcoritamab. It includes clinical trial data summaries, safety information (Important Safety Information), and company boilerplate. This type of announcement, which communicates a significant regulatory milestone (CHMP opinion leading to potential approval) and provides detailed clinical/product information, is characteristic of a press release or an official company update regarding product development and regulatory progress. It is not a formal SEC filing like a 10-K, nor is it a transcript, a dividend notice, or a management discussion. Given the context of a major regulatory step for a drug, it functions as a key piece of investor/public information. Since it is a detailed announcement about a regulatory event and product status, it fits best under the general category of Regulatory Filings (RNS) as a catch-all for important, non-standard announcements, or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but here it is focused purely on regulatory progress. However, since it is a specific announcement about a regulatory decision and product status, and not a general regulatory filing fallback, and it is not an ER (which focuses on financial results), RNS is the most appropriate general category for a non-standard, important company announcement that doesn't fit the other specific codes (like DIV, CAP, MANG, etc.). Given the nature of the content (regulatory news), RNS is the best fit among the available options for a non-financial results announcement.
2023-07-21 English
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Regulatory Filings Classification · 1% confidence The document is a press release issued by Genmab announcing a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding a drug candidate. This is a standard corporate regulatory announcement regarding product development and regulatory status, which falls under the 'Regulatory Filings' (RNS) category as it does not fit into specific financial reporting or governance categories.
2023-07-21 Danish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.